Raymond James stock price target raised to $181 from $174 at KBW

Published 23/10/2025, 14:26
Raymond James stock price target raised to $181 from $174 at KBW

Investing.com - Keefe, Bruyette & Woods raised its price target on Raymond James (NYSE:RJF) to $181.00 from $174.00 on Thursday, while maintaining a Market Perform rating on the financial services company’s stock.

The price target increase follows Raymond James’ fiscal fourth-quarter 2025 performance, which exceeded analyst expectations. The company reported GAAP earnings per share of $2.95, surpassing KBW’s estimate of $2.62 by $0.33.

On an adjusted basis, Raymond James delivered earnings per share of $3.11, exceeding KBW’s estimate of $2.69 by $0.42 and beating the consensus forecast of $2.77 by $0.34.

KBW attributed the earnings outperformance primarily to stronger results in Raymond James’ Capital Markets segment, which contributed approximately $0.16 to the earnings beat, along with a lower tax rate that added about $0.21.

The investment firm raised its forward earnings estimates for Raymond James based on higher cash balances and stronger Capital Markets performance assumptions, supporting the new $181 price target.

In other recent news, Raymond James Financial Inc . reported robust fourth-quarter earnings for fiscal year 2025, surpassing analyst expectations. The company posted an adjusted earnings per share of $3.11, outpacing the forecasted $2.82, and exceeded revenue predictions with $3.73 billion compared to the expected $3.64 billion. Following these results, BMO Capital adjusted its price target for Raymond James to $182, maintaining a Market Perform rating, after the company reported earnings per share of $3.12, which exceeded both BMO’s estimate and consensus expectations. Additionally, Citizens raised its price target for Raymond James to $190, citing a positive growth outlook and increased its fiscal year 2026 earnings per share estimate to $12.55, positioning it 7% above the current consensus. These developments reflect a positive response from analyst firms to Raymond James’ financial performance and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.